- Biocept (NASDAQ: BIOC) announces the pricing of an underwritten public offering of 9,100,000 shares of its common stock and warrants to purchase up to an aggregate of 9,100,000 shares of its common stock at a combined offering price of $1.10.
- The warrants will have a per share exercise price of $1.10, are exercisable immediately and will expire five years from the date of issuance.
- The gross proceeds to Biocept from this offering are expected to be approximately $10,010,000.
- Roth Capital Partners and Feltl and Company are acting as joint book-running managers for the offering.
- Biocept is a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer.
- BIOC -12.4% premarket to $1.04.
- Source: Press Release